Long regarded as an epicenter of drug-resistant malaria, Southeast Asia continues to provide new challenges to the control of Plasmodium falciparum malaria. Recently,
Background
As malaria endemic countries strive toward malaria elimination, one of the main obstacles is the continued availability of efficacious drugs. In Southeast Asia, drug resistance is wide-spread with the most recent emergence to artemisinin combination therapies (ACTs), which are currently used as first-line treatment regimens.
[1] The declining efficacy of ACTs in recent years can be largely attributed to rising resistance to artemisinin partner drugs, notably piperaquine. Dihydroartemisinin-piperaquine (DHA-PPQ) was introduced as the first-line treatment for malaria in 2008 in Cambodia, following partner drug resistance to artesunate-mefloquine (AS-MQ), the ACT used prior to 2008. Since 2012-2013, studies in Cambodia have shown declining efficacy to piperaquine in vitro, and subsequent increases in clinical treatment failures [2] [3] [4] [5] [6] [7] .
Genomic studies carried out in parallel with samples from these clinical efficacy studies have shown that there are multiple signals across the parasite genome that associate with both in vitro piperaquine resistance and clinical treatment failures [8, 9] . Specifically, a gene duplication within the plasmepsin multi-gene cluster on the parasite chromosome 14 and a non-synonymous SNP in a putative exonuclease gene (PF3D7_1362500) on chromosome 13, exo-E415G. Additional work also points to mutations in the chloroquine resistance transporter gene, pfcrt that can confer differing levels of piperaquine resistance in field and lab isolates [10, 11] .
The duplication encompasses plasmepsin 2 and a hybrid of the plasmepsin 1 and 3 genes and was highly correlated (adjusted hazard-ratio 16.7) with parasite recrudescence following adequate drug treatment with DHA-PPQ. This effect holds in the artemisinin resistance associated kelch13 propeller (K13) domain mutant populations [12] (adjusted hazard-ratio 5.2) suggesting an independent mechanism [8] Members of the plasmepsin gene family in P. falciparum are involved in the hemoglobin degradation pathway, specifically in the formation of hemozoin [13] . As the parasites digest hemoglobin and release heme, toxic by-products that cause oxidative stress are formed and the conversion of intermediates to inert hemozoin crystals detoxifies the harmful byproducts in the hemoglobin digestion pathway. The plasmepsin enzymes are redundant and other enzymes also facilitate the hemoglobin digestion pathway, including facilysins and falcipains. [14] [15] [16] The main duplication in plasmepsin 2/3 observed in Southeast Asia has a conserved break-point within the distal end of plasmepsin 3 and includes complete duplication of the plasmepsin 2 gene. In the same studies, an association was seen between increased copy numbers of pfmdr1 and low piperaquine IC 50 , and very few cases where both plasmepsin 2/3 and pfmdr1 were duplicated within the same parasite. It is unknown if the association between decreased piperaquine IC 50 and single copy pfmdr1 is due to a drug effect, or is due to the expansion of piperaquine resistance on a mefloquine sensitive parasite line. With the observation of possible counteracting resistance mechanisms, it has been suggested to re-introduce mefloquine to areas of emerging piperaquine resistance, or to combine mefloquine into a triple ACT (TACT) with piperaquine. Both options are currently being investigated [17] .
Monitoring this molecular marker of piperaquine resistance is essential to determine the frequency in populations which use DHA-PPQ as well as to determine if it appears in new parasite populations. We developed a TaqMan based quantitative PCR (qPCR) to measure the copy number of plasmepsin 2 within the duplicated region, and have also combined it with a TaqMan assay that can detect increased copy numbers of pfmdr1.
This single reaction multiplex qPCR can be used to efficiently monitor resistance to both piperaquine and mefloquine, a desirable prospect as mefloquine is in discussion for reintroduction to Cambodia in TACTs. We have also developed a PCR based breakpoint assay for detection of the hybrid sequence created as a result of the plasmepsin 2/3 duplication. This assay can be used in in conjunction with the qPCR assays and/or in low-resource settings where qPCR is infeasible.
Methods

Samples
Laboratory isolates used in qPCR validation were obtained from a clinical trial carried out in 3 sites in Cambodia between 2012 and 2013 [2] . Blood samples from this study were taken as whole-blood venous draws following malaria diagnosis and from an initial finger prick dried blood spot (DBS). A subset of DNA samples extracted from the venous blood were whole-genome sequenced and pfmdr1 and plasmepsin 2 copynumbers were called from sequence data according to Amato et al.[8] . Additional field derived isolates (after 2013) from clinical trials performed by the NIH at the same 3 sites in Cambodia as above were used to test ongoing copy-number polymorphisms (clinicaltrials.gov ID: NCT01736319).
Quantification of plasmepsin 2, plasmepsin3, and pfmdr1 by real-time PCR
Primers for both plasmepsin 2 and plasmepsin 3 were designed using GenScript online tool (https://www.genscript.com/tools/) to match the T m of the previously described pfmdr1 TaqMan assay [18] . Plasmepsin 2 primers (forward -5'-ATGGTGATGCAGAAGTTGGA-3', reverse -5'-AACATCCTGCAGTTGTACATTTAAC-3') and plasmepsin 3 primers (forward -5'-CCACTTGTGGTAACACGAAATTA-3'; reverse -5'-TGGTTCAAGGTATTGTTTAGGTTC-3') were selected to match the optimized reaction conditions of the pfmdr1 primers (forward 5'-TGCATCTATAAAACGATCAGACAAA-3', reverse 5'-TCGTGTGTTCCATGTGACTGT-3'. For the plasmepsin assay the same β-tubulin single copy reference primers (forward 5' -TGATGTGCGCAAGTGATCC-3', reverse 5'-TCCTTTGTGGACATTCTTCCTC-3') were used as in the pfmdr1 assay. First, the two-probe assay with either plasmepsin 2 (5'Fam-CAGGATCTGCTAATTTATGGGTCCCA-3'BHQ-2) or plasmepsin 3 (5'Fam-CCAACACTCGAATATCGTTCACCAA-3'BHQ-2) and beta-tubulin (5'MAX-TAGCACATGCCGTTAAATATCTTCCATGTCT-3'BHQ-1) was validated first using DNA from whole-blood extracted DNA and compared with copy-number estimates called from whole-genome sequence data. The plasmepsin 2 probe set was then multiplexed with pfmdr1 (5' Cy5-TTTAATAACCCTGATCGAAATGGAACCTTTG-3'BHQ-2) and then tested using DNA extracted from DBS in the same set of samples. All primers and probes were ordered from Integrated DNA Technologies, Inc.. Reactions were carried out in 25μl volumes in 96 well plates (Star Labs) on a Roche 480 LightCycler. For each reaction we used 2X Concentrated Roche LightCycler 480 Probes Master (containing FastStart Taq DNA Polymerase), 300 nmol/L of each plasmepsin 2 or plasmepsin 3, pfmdr1, and β-tubulin primers, 100 nmol/L of each probe, and 2-5 μl of sample DNA.
PCR cycling conditions had an initial step of 95 o C for 10 minutes followed by 50 cycles of 95 o C for 15 seconds and 58 o C for 60 seconds. To calculate the fold-change we used the ΔΔCt method, ΔΔCt = (Ct TE -Ct HE ) -(Ct TC -Ct HC ) where T is the test gene (either plasmepsin 2, plasmepsin 3, or pfmdr1), H is the reference gene (β-tubulin), E is the experimental sample, and C is the control sample (for all tests we used 3D7 as the single copy control). We calculated relative expression as 2 -ΔΔCt .
SYBR green validation of plasmepsin 2 copy number using quantitative PCR
PCR primers for estimating plasmepsin 2/3 copy number amplification were designed manually inside the plasmepsin 2 gene (forward -5'-CTTATACTGCTTCAACATTTGATGGTATCCTTGG-3'; reverse -5'-GGTTAAGAATCCTGTATGTTTATCATGTACAGGTAAG-3'). Previously described primers for P. falciparum lactate dehydrogenase (ldh) [19] , were used as the control for a single copy gene (forward -5'-AGGACAATATGGACACTCCGAT-3'; reverse -5'-TTTCAGCTATGGCTTCATCAAA-3'). Quantitative PCR reactions were carried out in 20 μl volumes in a 96-well plate (Bio-Rad, Hercules, CA) containing 10 μl SensiFAST SYBR No-ROX mix (2x) (Bioline Inc.,Taunton, MA), 300 nM of each primer, and 2 μl genomic DNA. Reactions were performed using a CFX Connect Real-Time PCR Detection System (Bio-Rad) using the following conditions: 5 minutes at 95°C, followed by 40 cycles of 10 seconds at 95°C, 20 seconds at 58°C, and 20 seconds at 60°C.
Relative copy number was calculated on the basis of the 2 -ΔΔCt method for relative quantification.
Δ Δ
Ct was calculated as (Ct ldh -Ct pfplasmepsin2 ) -(Ct ldh cal -Ct pfplasmepsin2 cal ), where cal is the calibration control of genomic 3D7 DNA with one copy of both ldh and plasmepsin2. DNA from an isolate with two copies of plasmepsin 2/3 (PH1387-C)[2] was used as an internal plate control. All samples were analyzed in triplicate and each plate was replicated in triplicate.
Plasmepsin 2/3 Duplication Breakpoint PCR Assay
Whole genome sequencing (WGS) data from P. falciparum genomic DNA collected during field studies in Cambodia was used to detect the plasmepsin 2/3 gene amplification as previously reported [2, 8] . With the available WGS data, the breakpoint of the plasmepsin 2/3 amplification was used to manually design PCR primers to amplify the region surrounding the breakpoint. Primers AF (forward 5'-CCACGATTTATATTGGCAAGTTGATTTAG -3') and AR (reverse 5'-CATTTCTACTAAAATAGCTTTAGCATCATTCACG-3') amplify a 623 bp product surrounding the breakpoint located at the 3' end of plasmepsin 1. Primers BF (forward -5'-CGTAGAATCTGCAAGTGT TTTCAAAG-3') and BR (reverse 5'-AATGTTATAAATGCAATATAATCAAACGACATCAC-3') amplify a 484 bp product surrounding the breakpoint located at the 3' end of plasmepsin 3. BF + AR amplify the junction between the breakpoint and produce a 497 bp product in isolates with plasmepsin 2/3 amplifications. These primers face opposite directions in samples without duplications and are not expected to amplify a product in single copy isolates.
Both control (AF + AR; BF+ BR) and duplication (BF + AR) primer sets were used with all samples and one copy isolates were only noted if the control primer sets amplified a product and duplication PCR was negative. Two or more copies were annotated as >1 μ l final volume with water. PCR conditions were: 92°C for 2 minutes, followed by 30 cycles of 92°C for 30 seconds, 59°C for 30 seconds, 66°C for 1.5 minutes, followed by a 1 minute extension at 66°C.
Results
Validation of copy number assays
Assays for plasmepsin 2 and plasmepsin 3 were designed and compared to determine if both genes could serve as markers for the entire duplication. For surveillance purposes the plasmepsin 2 assay was multiplexed with an existing pfmdr1 TaqMan assay. Both reference laboratory strains and culture-adapted field isolates were used to test the repeatability of each assay. The 3D7 isolate has single copies of all genes being tested while the Dd2 parasite has a duplication of the pfmdr1 gene and the field isolates PH1265-C and PH1387-C have duplications of the plasmepsin 2/3 complex.
Two field isolates (PH1097-C and PH1310-C) have single copies of all genes and were used as baseline controls. Individual plasmepsin assays and the combined plasmepsin 2 -pfmdr1 assay showed high replicability across duplicates (Table 1) . We then tested each assay from DNA extracted from whole blood for 67 patient samples. Copy number estimates from both the plasmepsin 2 and plasmepsin 3 assays were compared and were in 100% concordance across all samples extracted from venous blood. Fold-change values were comparable across both assays. Fifty-six of the 67 tested samples had WGS data available and had plasmepsin 2/3 copy-number estimates available; 53 of the 56 samples with copy-number estimates from WGS had the same estimate from qPCR, with the discrepancies being 1 sample called 2 copies by qPCR and 3 copies by WGS and 2 samples with 4 copies by qPCR and 3 copies by WGS. WGS estimates were used to define the relative expression boundaries between copy number estimates, and relative-expression values were lower in whole-blood extracted samples than in cultured laboratory isolates ( Figure 1A ). We observed a high proportion of the exo-E415G mutation among plasmepsin 2 multi-copy parasites ( Figure   1 ). Exo-415 calls were extracted from samples with available WGS data [8] .
To validate the copy number estimates, available samples were tested at the National
Institutes of Health (NIH) in the Laboratory of Malaria and Vector Research (LMVR) in
Bethesda, MD, USA using a separately developed SYBR-green based approach. Of the 31 samples available at both laboratories, 29 samples matched in copy number estimate with one sample being called 2 copies by TaqMan and 3 copies by SYBRgreen, and one sample being called 3 copies by TaqMan and 2 copies by SYBR-green.
All dual-tested samples that had copy number estimates from both the SYBR-green method and WGS were in 100% concordance.
Duplication breakpoint assay validation
We designed PCR primers that amplify the breakpoint of the plasmepsin 2/3 amplification observed in Cambodian isolates (Figure 2A ). Our breakpoint assay identifies copy number amplification in isolates that contain 2 or greater copies of plasmepsin 2 and 3 ( Figure 2B ). As expected, no PCR products were observed in samples with a single copy of plasmepsin 2/3 ( Figure 2B ). Control primers confirmed that the regions surrounding the plasmepsin 2/3 amplification were present in all isolates ( Figure 2C ).
Further verification of the breakpoint assay was performed via sequence analysis of the BF + AR PCR product. Sequence data revealed the same breakpoint location as observed by WGS [8] . All Cambodian samples that were positive for plasmepsin 2/3 amplification as detected by the breakpoint assay (>1 copy) were in 100% concordance with qPCR and WGS data that called 2 or more copies of plasmepsin 2. Sequencing chromatogram review of PCRs representing 2 and 3 copy samples showed that the Amplification primer set BF + AR amplifies a product in an isolate with two copies (PH1387-C) and three copies (PH1265-C) of plasmepsin 2/3. No product is observed for the single copy (PH1310-C) isolate or in the DNA-negative control (-). C. Control primers amplify a product in the single copy (PH1310-C) and multi-copy isolates (PH1387-C; PH1265-C). No product is observed in the DNA-negative control (-) . e e an breakpoints for representative 2 and 3 copy samples were identical. These sequencing results combined with the identical PCR sizes for all isolates indicates that the breakpoint is identical in all Cambodian isolates tested to date.
To test the utility of using the breakpoint assay for rapid surveillance of large sample sizes for which WGS data is not yet completed or available, we analyzed the presence of amplification in an additional 99 samples. We found that 93/99 (94%) samples tested with the breakpoint PCR assay matched qPCR data for the same samples. The six non-concordant samples were repeated, always producing the same results with the breakpoint detecting a copy-number increase and the qPCR single-copy. These results suggest that the breakpoint PCR assay is more sensitive than the qPCR assay for detecting minor clones containing the duplication in field isolates.
Copy number surveillance in Cambodia
To test the feasibility of using this assay as a surveillance tool, we performed the samples were available for analysis using both qPCR assays and had an 88% overall concordance, with only 6 (3%) samples having a discrepancy between calling a single versus multi-copy parasite. Most differences were between calling 2 versus 3 copies in either assay. Additionally, 71 samples that were either unavailable for DBS extraction or failed TaqMan qPCR were able to be typed by the SYBR-green method, giving copynumber estimates for 509 total samples. Samples with qPCR estimates in multiple sample types (whole-blood and DBS) were used to define relative expression limits between number of copies. We noticed a drop in relative expression in samples from DBS compared to whole-blood samples but confirmed multiple copies by the breakpoint assay, as well as observing exo-E415G SNPs among multi-copy samples ( Figure   1B ).
We observed an increase in multi-copy plasmepsin 2 each year in both Pursat and Preah Vihear, but did not observe any multi-copy containing parasites in Ratanakiri until 2014 when they were observed in 17% of parasites analyzed. We also observed an increase in parasites containing 3 copies of plasmepsin 2 from 2012/13 to 2014/15 to where they are now the majority (64%). There was also a large increase in multi-copy containing parasites in Preah Vihear from 2013 (29%) to 2014 (87%) ( Figure 3A ).
Among all 438 samples with pfmdr1 copy-number estimates, only 10 (2%) had multiple copies and no parasites with duplications were seen in the most recently sampled year for each site ( Figure 3B ).
Discussion
Our newly developed TaqMan assay accurately determines plasmepsin 2/3 and mdr1 gene amplifications in samples from DBS and can be performed using standard lab equipment and a suitable qPCR machine. The specificity of TaqMan probes combined with the different absorbance spectra of labeling dyes create a system for typing the reference gene simultaneously with one or more experimental genes, making it higher throughput than SYBR-green based methods. Our method shows high typeability in samples collected on dried filter paper blood spots making it ideal for surveillance of populations across wide areas. The breakpoint PCR assay also effectively determines increased plasmepsin 2/3 copy number in field isolates and can be used in areas where qPCR is infeasible. The sensitivity of this assay enables the detection of minor clones, which proves advantageous, given the potential for polyclonal infections. However, a notable disadvantage of this method is the inability to distinguish the relative copy number (2, 3, or 4+ copies vs. >1) in comparison with qPCR. The breakpoint assay was also designed with primers specific to the plasmepsin 2/3 breakpoint observed in re s Cambodian field isolates [8] . The PCR primers used to detect the Cambodian breakpoint observed to date may not amplify a product in samples that contain different breakpoints. As previous studies have suggested [20, 21] , copy number variations in the same gene can arise independently on different genetic backgrounds and result in distinct molecular breakpoints of amplification. Since qPCR methods do not rely on the location of primers in reference to an estimated breakpoint, they can be used broadly.
Furthermore, the high-throughput potential of the qPCR assay to type multiple genes in the same assay while providing actual copy number estimates makes the TaqMan assay the preferred method in areas where qPCR is possible. In 2014 the first report of DHA-PPQ treatment failures was published [7] . Because of an ever-increasing catalogue of sequenced samples and clinical and laboratory studies, a putative marker of drug resistance was published less than two years after the first reports of resistance [8, 9] , with additional studies identifying new markers in pfcrt shortly after [10, 11] . Being able to extensively type variation by WGS made it possible to identify the association of increased piperaquine IC 50 values with both SNPs and a copy-number variation. The copy-number variation at the plasmepsin 2/3 locus showed high correlation with the phenotype and the new assays for detection will assist in monitoring its frequency in established populations, and can also monitor unaffected populations to check for new emergence or spread.
For a molecular marker to be effective in surveillance it must be easily typed in fieldderived samples. Most molecular markers of P. falciparum drug resistance are SNPs and can be typed by simple PCR assays [26] [27] [28] [29] [30] [31] , although copy-number markers exist for mefloquine [18] and antifolates[32] they are more difficult to type. Quantitative PCR makes for an easy and inexpensive method to determine copy number in samples, and unlike breakpoint assays, qPCR can determine the number of copies. It is not known if more than 2 copies of plasmepsin 2/3 have a phenotypic effect but the increase in samples with 3 or more copies suggest some sort of selective mechanism. It is possible that a third copy of plasmepsin 2/3 prevents a loss of resistance if the duplication is unstable and an extra copy is lost, therefore the third copy would act as a "buffer.
Recent studies in Plasmodium have provided insight into the functional role of the plasmepsins in response to piperaquine pressure. Loesbanluechai et al. 2018 showed that overexpression of plasmepsin 2 and plasmepsin 3 in the 3D7 parasite background did not change parasite susceptibility to piperaquine, artemisinin, or chloroquine [33] .
Other studies have suggested that plasmepsin 2 and plasmepsin 3 knockouts in the same 3D7 background showed decreased piperaquine survival as measured by IC50
values [34] . Thus, additional functional work is needed to fully understand the relevance of the plasmepsin 2/3 gene amplification in conferring any survival or fitness advantages in response to PPQ pressure.
Mefloquine is currently being considered for re-introduction as a partner drug for artemisinin either as a dual or triple combination [17] . It was removed as the first line treatment following widespread resistance via a duplication in the pfmdr1 gene. Since mefloquine's removal as a nationally-recommended treatment the levels of pfmdr1 multi-copy number parasites has fallen and now is no longer detected in our samples from 3 distant sites in Cambodia (Figure 3 ). It has been suggested that a counter-acting mechanism of action has selected against multiple copies of pfmdr1 in parasites subjected to piperaquine. This is feasible but will require confirmation, while another possibility is that the plasmepsin 2/3 multi-copy parasites emerged on a pfmdr1 single copy parasite background and it is this lineage(s) that have expanded.
In order to effectively monitor the spread of antimalarial drug resistance, it is imperative to have robust, high-throughput methods for detecting genetic markers of resistance.
Accurate and timely surveillance of drug resistance markers informs treatment strategies and aids in maintaining and prolonging efficacy of the limited selection antimalarial drugs available. Our TaqMan qPCR and breakpoint assays are tools that can be widely used to track plasmepsin 2/3 amplification as a marker of piperaquine resistance. As mefloquine is being reintroduced in multiple Southeast Asian countries, our multiplex TaqMan qPCR assay should prove useful in monitoring for genetic markers of both mefloquine and piperaquine resistance.
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